Equities research analysts expect NovaBay Pharmaceuticals, Inc. (NYSE:NBY) to post ($0.12) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for NovaBay Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.14). NovaBay Pharmaceuticals reported earnings of ($0.36) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 66.7%. The firm is scheduled to report its next quarterly earnings report on Thursday, August 10th.
According to Zacks, analysts expect that NovaBay Pharmaceuticals will report full year earnings of ($0.54) per share for the current financial year, with EPS estimates ranging from ($0.60) to ($0.47). For the next financial year, analysts anticipate that the firm will report earnings of ($0.07) per share, with EPS estimates ranging from ($0.13) to ($0.02). Zacks’ EPS averages are an average based on a survey of research analysts that cover NovaBay Pharmaceuticals.
NBY has been the subject of several recent research reports. Roth Capital initiated coverage on shares of NovaBay Pharmaceuticals in a research note on Monday, June 5th. They issued a “buy” rating and a $5.50 target price for the company. Zacks Investment Research downgraded shares of NovaBay Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, April 11th. Laidlaw initiated coverage on shares of NovaBay Pharmaceuticals in a research note on Monday, March 27th. They issued a “buy” rating and a $10.00 target price for the company. HC Wainwright set a $6.00 target price on shares of NovaBay Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, March 26th. Finally, Maxim Group reiterated a “hold” rating on shares of NovaBay Pharmaceuticals in a research note on Saturday, May 13th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. NovaBay Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $7.00.
NovaBay Pharmaceuticals (NBY) traded down 7.23% during mid-day trading on Monday, reaching $3.85. 12,144 shares of the company’s stock were exchanged. NovaBay Pharmaceuticals has a 52-week low of $2.12 and a 52-week high of $5.29. The company has a 50-day moving average of $2.92 and a 200-day moving average of $3.51. The stock’s market cap is $58.94 million.
TRADEMARK VIOLATION WARNING: This piece was first posted by WKRB News and is the property of of WKRB News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.wkrb13.com/markets/2299322/0-12-eps-expected-for-novabay-pharmaceuticals-inc-nby-this-quarter-2.html.
NovaBay Pharmaceuticals Company Profile
NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2299322/0-12-eps-expected-for-novabay-pharmaceuticals-inc-nby-this-quarter-2.html
Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.